Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotatic Radiation Therapy in Patients with Advanced Solid Malignancies

Trial Profile

Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotatic Radiation Therapy in Patients with Advanced Solid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Adrenal cancer; Liver cancer; Lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jun 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
    • 20 Jun 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 20 Sep 2016 Results from Phase I part of this trial (n=35) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top